Immunotherapy in NSCLC Patients with Brain Metastases.
NSCLC
brain
immunotherapy
metastases
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
25 Jun 2022
25 Jun 2022
Historique:
received:
15
05
2022
revised:
16
06
2022
accepted:
23
06
2022
entrez:
9
7
2022
pubmed:
10
7
2022
medline:
14
7
2022
Statut:
epublish
Résumé
Approximately 40% of unselected non-small cell lung cancer (NSCLC) patients develop brain metastases (BMs) during their disease, with considerable morbidity and mortality. The management of BMs in patients with NSCLC is a clinical challenge and requires a multidisciplinary approach to gain effective intracranial disease control. Over the last decade, immune checkpoint inhibitors (ICIs) have emerged as a game-changer in the treatment landscape of advanced NSCLC, with significant improvements in survival outcomes, although patients with BMs are mostly underrepresented in randomized clinical trials. Moreover, the safety and activity of ICIs and radiotherapy combinations compared with single-agent or sequential modalities is still under evaluation to establish the optimal management of these patients. The aim of this review is to summarize the state-of-the-art of clinical evidence of ICIs intracranial activity and the main challenges of incorporating these agents in the treatment armamentarium of NSCLC patients with BMs.
Identifiants
pubmed: 35806080
pii: ijms23137068
doi: 10.3390/ijms23137068
pmc: PMC9267075
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Clin Lung Cancer. 2021 Jan;22(1):58-66.e3
pubmed: 33279417
J Immunother Cancer. 2019 May 6;7(1):121
pubmed: 31060602
Anticancer Res. 2019 Aug;39(8):4265-4271
pubmed: 31366516
J Neurosurg. 2017 Nov;127(5):1007-1014
pubmed: 28059663
Lung Cancer. 2019 Feb;128:105-112
pubmed: 30642441
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Front Oncol. 2021 Nov 02;11:772789
pubmed: 34796118
Future Oncol. 2021 Feb;17(6):637-648
pubmed: 33300372
Int J Mol Sci. 2021 Oct 27;22(21):
pubmed: 34769050
Cancer Treat Rev. 2016 Apr;45:139-62
pubmed: 27019457
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):343-9
pubmed: 23462419
J Clin Oncol. 2022 Feb 10;40(5):492-516
pubmed: 34932393
Lung Cancer. 2019 Mar;129:35-40
pubmed: 30797489
Lancet Oncol. 2021 Feb;22(2):198-211
pubmed: 33476593
Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):624-629
pubmed: 29678530
Cancer Radiother. 2021 Jul;25(5):432-440
pubmed: 33836954
Lancet Respir Med. 2019 May;7(5):387-401
pubmed: 30922878
Sci Transl Med. 2017 Apr 12;9(385):
pubmed: 28404866
J Clin Oncol. 2022 Jul 20;40(21):2295-2306
pubmed: 35658002
Clin Cancer Res. 2014 May 1;20(9):2424-32
pubmed: 24583799
Pharmacol Ther. 2018 Jun;186:130-137
pubmed: 29352857
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Neuro Oncol. 2019 Aug 5;21(8):1060-1068
pubmed: 30796838
Cell. 2017 Sep 7;170(6):1120-1133.e17
pubmed: 28803728
Radiother Oncol. 2019 Jan;130:104-112
pubmed: 30241791
Eur J Cancer. 2017 Apr;75:141-149
pubmed: 28222308
J Thorac Oncol. 2017 Feb;12(2):194-207
pubmed: 27729297
Immunity. 2013 Jul 25;39(1):74-88
pubmed: 23890065
Ann Oncol. 2021 Nov;32(11):1332-1347
pubmed: 34364998
Neuro Oncol. 2020 Jan 11;22(1):17-30
pubmed: 31437274
J Clin Oncol. 2018 Oct 1;36(28):2872-2878
pubmed: 30125216
J Clin Oncol. 2021 Mar 1;39(7):723-733
pubmed: 33449799
Lung Cancer. 2021 Jul;157:40-47
pubmed: 33980420
BMC Cancer. 2019 Jan 7;19(1):19
pubmed: 30616523
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Clin Cancer Res. 2017 Sep 15;23(18):5514-5526
pubmed: 28533222
Front Immunol. 2022 Mar 29;13:852811
pubmed: 35422812
Cell Death Discov. 2016 Oct 03;2:16025
pubmed: 27752361
J Neurooncol. 2014 May;118(1):109-16
pubmed: 24532241
J Thorac Oncol. 2018 Nov;13(11):1733-1742
pubmed: 29775807
Lancet Oncol. 2012 May;13(5):459-65
pubmed: 22456429
Eur J Cancer. 2019 Dec;123:72-80
pubmed: 31671314
JTO Clin Res Rep. 2021 Jul 01;2(8):100205
pubmed: 34590048
J Clin Invest. 2014 Feb;124(2):687-95
pubmed: 24382348
Ann Oncol. 2021 Sep;32(9):1137-1147
pubmed: 34139272
Curr Oncol Rep. 2012 Feb;14(1):48-54
pubmed: 22012633
Lancet Oncol. 2020 May;21(5):655-663
pubmed: 32251621
Cancers (Basel). 2021 Nov 20;13(22):
pubmed: 34830977
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
ESMO Open. 2022 Jun;7(3):100465
pubmed: 35427835
J Clin Oncol. 2020 May 10;38(14):1505-1517
pubmed: 32150489
ESMO Open. 2016 Mar 16;1(2):e000024
pubmed: 27843591
Ther Adv Med Oncol. 2020 Oct 26;12:1758835920967237
pubmed: 33403011
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Sci Transl Med. 2017 Apr 12;9(385):
pubmed: 28404865
J Thorac Oncol. 2021 Nov;16(11):1883-1892
pubmed: 34265431
Cancer Res. 2015 Dec 1;75(23):5034-45
pubmed: 26573793
Lung Cancer. 2021 Jan;151:60-68
pubmed: 33246646
Cancers (Basel). 2021 Apr 29;13(9):
pubmed: 33946751
J Thorac Oncol. 2019 Jul;14(7):1244-1254
pubmed: 30780002
J Immunother Cancer. 2018 Jun 4;6(1):46
pubmed: 29866197
Front Oncol. 2018 Apr 11;8:88
pubmed: 29696132
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):916-925
pubmed: 29485071
Lancet. 2021 Feb 13;397(10274):592-604
pubmed: 33581821
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
J Exp Clin Cancer Res. 2019 Jun 13;38(1):255
pubmed: 31196207